Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Clearmind Medicine Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CMND
Nasdaq
8731
https://www.clearmindmedicine.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Clearmind Medicine Inc
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
- Apr 17th, 2024 11:49 am
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
- Apr 10th, 2024 11:17 am
Clearmind Medicine CEO Issues Letter to Shareholders
- Apr 9th, 2024 12:07 pm
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
- Mar 27th, 2024 1:12 pm
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
- Mar 19th, 2024 11:55 am
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
- Mar 13th, 2024 12:14 pm
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
- Mar 13th, 2024 11:30 am
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
- Feb 27th, 2024 12:58 pm
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
- Feb 27th, 2024 12:58 pm
Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours
- Feb 26th, 2024 3:37 pm
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
- Feb 23rd, 2024 12:06 pm
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
- Feb 20th, 2024 12:14 pm
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
- Feb 20th, 2024 12:14 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Feb 11th, 2024 6:59 pm
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
- Feb 5th, 2024 12:51 pm
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
- Feb 1st, 2024 1:15 pm
Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
- Jan 16th, 2024 5:20 pm
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
- Jan 16th, 2024 4:19 pm
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
- Jan 11th, 2024 2:28 pm
Clearmind Medicine Completed Type A Meeting with the FDA
- Jan 10th, 2024 12:18 pm
Scroll